At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHAT Phathom Pharmaceuticals
Post-Mkt 03-26 18:53:21 EDT
10.79
+0.32
+3.06%
盘后10.79
+0.000.00%
16:20 EDT
High10.92Low10.35Vol762.91K
Open10.45D1 Closing10.47Amplitude5.49%
Mkt Cap850.24MTradable Cap621.15MTotal Shares78.80M
T/O8.17MT/O Rate1.33%Tradable Shares57.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Phathom Pharmaceuticals management to meet with Cantor
TIPRANKS  ·  03-24
Phathom Pharmaceuticals management to meet with Cantor
Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up
TIPRANKS  ·  03-05
Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up
Phathom Pharmaceuticals Is Maintained at Buy by Guggenheim
Dow Jones  ·  02-27
Phathom Pharmaceuticals Is Maintained at Buy by Guggenheim
Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim
TIPRANKS  ·  02-27
Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim
Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating
TIPRANKS  ·  02-27
Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating
Analysts’ Top Healthcare Picks: Phathom Pharmaceuticals (PHAT), Certara (CERT)
TIPRANKS  ·  02-27
Analysts’ Top Healthcare Picks: Phathom Pharmaceuticals (PHAT), Certara (CERT)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), BioLife Solutions (BLFS) and RxSight (RXST)
TIPRANKS  ·  02-27
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), BioLife Solutions (BLFS) and RxSight (RXST)
Phathom Pharmaceuticals Q4 revenue slightly beats expectations
Reuters  ·  02-26
Phathom Pharmaceuticals Q4 revenue slightly beats expectations
Phathom posts FY 2025 net revenues of USD 175.1 million, up 217%
Reuters  ·  02-26
Phathom posts FY 2025 net revenues of USD 175.1 million, up 217%
Phathom Pharmaceuticals Q4 Adj. EPS $(0.08) Beats $(0.38) Estimate, Sales $57.584M Beat $57.050M Estimate
Benzinga  ·  02-26
Phathom Pharmaceuticals Q4 Adj. EPS $(0.08) Beats $(0.38) Estimate, Sales $57.584M Beat $57.050M Estimate
BRIEF-Phathom Pharmaceuticals Q4 Net Income USD -21.148 Million
Reuters  ·  02-26
BRIEF-Phathom Pharmaceuticals Q4 Net Income USD -21.148 Million
Phathom Pharmaceuticals Inc Outlook 2026 Net Revenues of $320-$345 Mln
THOMSON REUTERS  ·  02-26
Phathom Pharmaceuticals Inc Outlook 2026 Net Revenues of $320-$345 Mln
Phathom Pharmaceuticals Inc: Operating Profitability Expected Beginning in Q3 2026 and for FY 2026
THOMSON REUTERS  ·  02-26
Phathom Pharmaceuticals Inc: Operating Profitability Expected Beginning in Q3 2026 and for FY 2026
Press Release: Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Dow Jones  ·  02-26
Press Release: Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  02-23
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals Inc. to Report Financial Results and Provide Business Update
Reuters  ·  02-17
Phathom Pharmaceuticals Inc. to Report Financial Results and Provide Business Update
Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR) and Phathom Pharmaceuticals (PHAT)
TIPRANKS  ·  01-22
Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR) and Phathom Pharmaceuticals (PHAT)
Assessing Phathom Pharmaceuticals (PHAT) Valuation After Recent Share Price Volatility
Simply Wall St.  ·  01-11
Assessing Phathom Pharmaceuticals (PHAT) Valuation After Recent Share Price Volatility
Phathom Pharmaceuticals Announces $130 Million Public Offering
TIPRANKS  ·  01-09
Phathom Pharmaceuticals Announces $130 Million Public Offering
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY)
TIPRANKS  ·  01-08
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY)

Introduction

Company Name.
Phathom Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Issue price:
--